149845-06-7 Usage
Uses
Used in Pharmaceutical Industry:
Saquinavir mesylate is used as an antiviral agent for the treatment of HIV infection. It works by inhibiting the HIV protease enzyme, which is essential for the replication of the virus within host cells. By blocking this enzyme, the virus cannot multiply, thus helping to control the infection and slow down the progression of the disease.
Used in Research and Development:
Saquinavir mesylate is also used in cell signaling and immunology studies. It serves as a valuable tool for researchers to understand the mechanisms of HIV infection and the role of protease enzymes in the viral life cycle. This knowledge can be applied to develop new therapeutic strategies and improve existing treatments for HIV.
Hazard
Moderately toxic by ingestion.
Biochem/physiol Actions
Saquinavir is an HIV Protease Inhibitor used in antiretroviral therapy. It inhibits both HIV-1 and HIV-2 proteases. Studies have also looked at saquinavir as a possible anti-cancer agent.
Check Digit Verification of cas no
The CAS Registry Mumber 149845-06-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,9,8,4 and 5 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 149845-06:
(8*1)+(7*4)+(6*9)+(5*8)+(4*4)+(3*5)+(2*0)+(1*6)=167
167 % 10 = 7
So 149845-06-7 is a valid CAS Registry Number.
InChI:InChI=1/C38H50N6O5.CH4O3S/c1-38(2,3)43-37(49)32-20-26-14-7-8-15-27(26)22-44(32)23-33(45)30(19-24-11-5-4-6-12-24)41-36(48)31(21-34(39)46)42-35(47)29-18-17-25-13-9-10-16-28(25)40-29;1-5(2,3)4/h4-6,9-13,16-18,26-27,30-33,45H,7-8,14-15,19-23H2,1-3H3,(H2,39,46)(H,41,48)(H,42,47)(H,43,49);1H3,(H,2,3,4)/t26-,27+,30-,31-,32-,33+;/m0./s1
149845-06-7Relevant academic research and scientific papers
NOVEL POLYMORPHS OF SAQUINAVIR
-
Page/Page column 3, (2012/02/15)
The present invention provides novel polymorphs of saquinavir, processes for their preparation and pharmaceutical compositions comprising them. The present invention also provides a process for purification of saquinavir. The present invention further provides a novel process for preparation of known saquinavir crystalline form I.
A PROCESS FOR THE PREPARATION OF SAQUINAVIR USING NOVEL INTERMEDIATE
-
Page/Page column 4-5, (2008/06/13)
The present invention provides a commercially viable process for preparing saquinavir and pharmaceutically acceptable acid addition salts thereof using novel intermediate. Thus, for example, N?2?-(2-quinolinylcarbonyl)-L-asparagine is reacted with pivaloyl chloride in methylene chloride in presence of triethyl amine to give pivaloyl N?2?-(2-quinolinylcarbonyl)-L-asparaginate, which is then condensed with [3S,4aS,8aS]-2-(3S-amino-2R-hydroxy-4-phenylbutyl)-N-(1,1-dimethylethyl)decahydro-3-isoquinoline carboxamide to give saquinavir, followed by treatment with methanesulfonic acid to give saquinavir mesylate.
